Cargando…
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
The mammalian Target of Rapamycin (mTOR) is an intracellular serine/threonine kinase that mediates intracellular metabolism, cell survival and actin rearrangement. mTOR is made of two independent complexes, mTORC1 and mTORC2, activated by the scaffold proteins RAPTOR and RICTOR, respectively. The ac...
Autores principales: | Lamanuzzi, Aurelia, Saltarella, Ilaria, Desantis, Vanessa, Frassanito, Maria Antonia, Leone, Patrizia, Racanelli, Vito, Nico, Beatrice, Ribatti, Domenico, Ditonno, Paolo, Prete, Marcella, Solimando, Antonio Giovanni, Dammacco, Francesco, Vacca, Angelo, Ria, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945497/ https://www.ncbi.nlm.nih.gov/pubmed/29755672 http://dx.doi.org/10.18632/oncotarget.25003 |
Ejemplares similares
-
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?()
por: Saltarella, Ilaria, et al.
Publicado: (2018) -
MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020) -
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study
por: Rao, Luigia, et al.
Publicado: (2018) -
Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016) -
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)